Pages that link to "Q42820571"
Jump to navigation
Jump to search
The following pages link to Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. (Q42820571):
Displaying 50 items.
- Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approaches (Q21129299) (← links)
- Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA (Q24324771) (← links)
- Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M31-15, which inhibits cell motility (Q24675573) (← links)
- Enhancing Cancer Immunotherapy Via Activation of Innate Immunity (Q26796313) (← links)
- NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy (Q26797345) (← links)
- Molecular recognition of gangliosides and their potential for cancer immunotherapies (Q26830588) (← links)
- Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients (Q33363235) (← links)
- A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group (Q33370628) (← links)
- Re-configuration of sphingolipid metabolism by oncogenic transformation (Q33649823) (← links)
- The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma (Q34186886) (← links)
- Anti-GD2 Strategy in the Treatment of Neuroblastoma (Q34243887) (← links)
- Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells (Q34287952) (← links)
- GD2-targeted immunotherapy and radioimmunotherapy (Q34625339) (← links)
- Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK. (Q35086721) (← links)
- Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety (Q35163167) (← links)
- Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness (Q35210792) (← links)
- Comparison of GD2 binding capture ELISA assays for anti-GD2-antibodies using GD2-coated plates and a GD2-expressing cell-based ELISA (Q35381031) (← links)
- Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy (Q35474060) (← links)
- Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma (Q35623435) (← links)
- Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow (Q35747067) (← links)
- Hybrid Theranostic Platform for Second Near-IR Window Light Triggered Selective Two-Photon Imaging and Photothermal Killing of Targeted Melanoma Cells. (Q35761139) (← links)
- Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor (Q36352014) (← links)
- Phase II trial of hu14.18-IL2 for patients with metastatic melanoma (Q36412879) (← links)
- Dinutuximab and Panobinostat (Q36572408) (← links)
- Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo: challenges and prospects (Q36685485) (← links)
- Enhancing both CT imaging and natural killer cell-mediated cancer cell killing by a GD2-targeting nanoconstruct (Q36795032) (← links)
- Immunology and immunotherapy of neuroblastoma (Q36856798) (← links)
- "Model t" cells: a time-tested vehicle for gene therapy (Q37201423) (← links)
- Immune therapies for neuroblastoma (Q37431356) (← links)
- Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy. (Q37592957) (← links)
- Correlation between positron emission tomography and Cerenkov luminescence imaging in vivo and ex vivo using 64Cu-labeled antibodies in a neuroblastoma mouse model (Q37687173) (← links)
- Anti-GD2 antibody therapy for GD2-expressing tumors (Q37702283) (← links)
- Treatment of high-risk neuroblastoma with anti-GD2 antibodies (Q37820755) (← links)
- Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy (Q37974938) (← links)
- Nanocarrier-mediated targeting of tumor and tumor vascular cells improves uptake and penetration of drugs into neuroblastoma. (Q38128317) (← links)
- Immunocytokines: a review of molecules in clinical development for cancer therapy (Q38132742) (← links)
- Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L. (Q38308633) (← links)
- Resveratrol augments ER stress and the cytotoxic effects of glycolytic inhibition in neuroblastoma by downregulating Akt in a mechanism independent of SIRT1. (Q38792925) (← links)
- Engineered T cells: the promise and challenges of cancer immunotherapy. (Q38828829) (← links)
- Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy (Q38916529) (← links)
- Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3. (Q39342110) (← links)
- High specificity targeting and detection of human neuroblastoma using multifunctional anti-GD2 iron-oxide nanoparticles. (Q39698027) (← links)
- Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma (Q39802101) (← links)
- Receptor-specific targeting with liposomes in vitro based on sterol-PEG(1300) anchors (Q39915400) (← links)
- Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma (Q39960663) (← links)
- Altered erythropoiesis and decreased number of erythrocytes in children with neuroblastoma (Q40053162) (← links)
- Mapping sites of herpes simplex virus type 1 glycoprotein D that permit insertions and impact gD and gB receptors usage. (Q40310537) (← links)
- Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults (Q40700335) (← links)
- Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients (Q40980342) (← links)
- A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2 (Q41171901) (← links)